GSK256073 acutely regulates NEFA levels via HCA2 agonism but does not achieve durable glycaemic control in type 2 diabetes. A randomised trial

European Journal of Pharmacology
R DobbinsAnne-Charlotte Le Monnier de Gouville

Abstract

This study investigated safety and efficacy of GSK256073, an in vitro potent, selective GPR109A agonist, for treatment of subjects with type 2 diabetes mellitus (Type 2 DM) poorly controlled with metformin alone. Patients with Type 2 DM (n=94) were enroled into this randomised, double-blind (sponsor unblinded), placebo-controlled, parallel group trial. Participants received placebo for two weeks before being randomised (2:2:2:2:1:1) to receive doses of GSK256073 5mg twice-daily (BID), 10mg once-daily (QD), 25mg BID, 50mg QD or placebo BID or QD in addition to their current metformin treatment. The primary efficacy endpoint was change from baseline in glycosylated haemoglobin (HbA1c) at week 12. The safety profile of GSK256073 did not significantly differ from that of placebo. Decreases from baseline in HbA1c were observed in all treatment groups but were not statistically significant compared to placebo; at week 12 a maximum decrease of 0.30% from placebo was reached in the GSK256073 50mg QD group. On day 2, GSK256073 significantly decreased non-esterified fatty acid (NEFA) (0-12h) concentrations but pharmacological activity was lost (5mg BID, 10mg QD, 25mg BID) or reduced (50mg QD) at week 6. Drug exposure demonstrated 2-fold ...Continue Reading

References

Jul 1, 1989·The Journal of International Medical Research·M LavezzariF Pamparana
Dec 1, 1993·Diabetic Medicine : a Journal of the British Diabetic Association·C SalorantaM R Taskinen
Jul 21, 2000·The Journal of Clinical Investigation·G I Shulman
Dec 23, 2008·Diabetes Research and Clinical Practice·Viswanathan MohanKeith D Kaufman
Jul 25, 2009·British Journal of Pharmacology·Helen Vosper
Aug 24, 2012·Science Translational Medicine·Brett LauringAndrew Plump

❮ Previous
Next ❯

Citations

Mar 5, 2016·Current Atherosclerosis Reports·Harsh Goel, Richard L Dunbar
Nov 7, 2015·Biochimie·Pauline MorignyDominique Langin
Jan 15, 2017·Trends in Endocrinology and Metabolism : TEM·Stefan Offermanns
Feb 3, 2018·British Journal of Pharmacology·Kyle W SloopFrancis S Willard
Dec 14, 2017·Pharmacological Reviews·Darren M RiddyChristopher J Langmead
Jan 19, 2019·Annals of Clinical and Translational Neurology·Pavan BhargavaPeter A Calabresi
Aug 23, 2017·Annual Review of Nutrition·John C Newman, Eric Verdin
Aug 31, 2019·Nutrients·Amélie I S SobczakAlan J Stewart
Jan 3, 2021·Progress in Lipid Research·Emeline RecazensDominique Langin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.